Q2 EPS Estimates for Viking Therapeutics Reduced by B. Riley

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Analysts at B. Riley dropped their Q2 2025 earnings per share (EPS) estimates for shares of Viking Therapeutics in a research note issued to investors on Thursday, April 24th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings per share of ($0.43) for the quarter, down from their previous forecast of ($0.33). B. Riley currently has a “Buy” rating and a $96.00 price target on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. B. Riley also issued estimates for Viking Therapeutics’ Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($2.41) EPS, FY2027 earnings at ($3.48) EPS and FY2028 earnings at ($2.92) EPS.

A number of other equities research analysts have also recently weighed in on VKTX. Scotiabank initiated coverage on Viking Therapeutics in a report on Thursday, February 13th. They set a “sector outperform” rating and a $102.00 price target for the company. Truist Financial restated a “buy” rating and issued a $75.00 target price (down from $95.00) on shares of Viking Therapeutics in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a research report on Thursday, April 24th. Morgan Stanley lowered their price objective on shares of Viking Therapeutics from $105.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, April 24th. Finally, Citigroup initiated coverage on shares of Viking Therapeutics in a research note on Friday, February 7th. They set a “neutral” rating and a $38.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $87.15.

Viking Therapeutics Trading Up 3.8 %

Shares of Viking Therapeutics stock opened at $25.94 on Monday. Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $81.86. The firm’s 50-day moving average price is $26.35 and its two-hundred day moving average price is $40.06. The stock has a market capitalization of $2.91 billion, a price-to-earnings ratio of -25.94 and a beta of 0.84.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). During the same quarter in the prior year, the business posted ($0.26) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year.

Institutional Investors Weigh In On Viking Therapeutics

Several large investors have recently modified their holdings of VKTX. Blue Trust Inc. increased its stake in Viking Therapeutics by 75.9% during the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 309 shares in the last quarter. YANKCOM Partnership bought a new position in Viking Therapeutics during the 4th quarter worth about $33,000. Parallel Advisors LLC lifted its holdings in shares of Viking Therapeutics by 64.8% in the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 536 shares in the last quarter. FIL Ltd boosted its position in shares of Viking Therapeutics by 116.8% during the fourth quarter. FIL Ltd now owns 1,203 shares of the biotechnology company’s stock worth $48,000 after buying an additional 648 shares during the period. Finally, NBC Securities Inc. grew its holdings in shares of Viking Therapeutics by 222,100.0% during the first quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company’s stock worth $53,000 after buying an additional 2,221 shares in the last quarter. 76.03% of the stock is currently owned by institutional investors.

Insider Transactions at Viking Therapeutics

In other Viking Therapeutics news, Director Sarah Kathryn Rouan acquired 1,240 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The shares were acquired at an average price of $24.15 per share, with a total value of $29,946.00. Following the purchase, the director now owns 1,240 shares of the company’s stock, valued at $29,946. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.10% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.